Jubilant Pharmova Secures USFDA Tentative Approval for Pantoprazole Oral Suspension, Eyes 2026 Launch
核心洞察
Jubilant Generics received tentative USFDA (搜索) approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet, following a successful pre-approval inspection at its Roorkee facility.
The tentative approval will convert to final approval upon patent expiry of the reference listed drug, expected in December 2026.
The approval strengthens Jubilant Pharmova's U.S. generics portfolio in the gastrointestinal therapy segment and positions the company for a prompt commercial launch.
Jubilant Pharmova Limited has announced that its subsidiary Jubilant Generics Limited has received tentative approval from the United States Food and Drug Administration (USFDA (搜索)) for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet. The approval follows the successful completion of a pre-approval inspection (PAI) conducted by the USFDA at the company's Solid Dosage Manufacturing Facility in Roorkee, marking a significant regulatory milestone for the Indian pharmaceutical company's U.S. generics expansion strategy.
The tentative approval positions Jubilant Generics to enter the U.S. market with a generic version of the proton pump inhibitor (PPI) indicated for gastrointestinal conditions, pending the expiration of the patent covering the currently listed Reference Listed Drug (RLD).
Regulatory Pathway and Timeline
The tentative approval is subject to the expiry of the patent on the current reference listed drug, which is expected in December 2026. Upon patent expiry, the tentative approval is anticipated to convert to final approval, enabling Jubilant Generics to launch the product commercially in the U.S. market without delay.
The disclosure was made to Indian stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the information was received on June 25, 2026, at 11:47 am IST. Jubilant Generics Limited operates as a subsidiary of Jubilant Pharma Limited, which is a wholly-owned subsidiary of Jubilant Pharmova Limited.
Strategic Implications for the Generics Portfolio
The tentative approval underscores Jubilant Pharmova's continued progress in expanding its U.S. generics portfolio, particularly within the gastrointestinal therapy segment. The company's ability to secure regulatory milestones following a successful pre-approval inspection at its Roorkee solid dosage facility demonstrates manufacturing compliance with USFDA (搜索) standards.
Once commercialization begins following final approval, the product could enhance Jubilant Pharmova's revenue prospects and competitive standing in the U.S. generics market. The prompt launch anticipated upon patent expiry reflects the company's readiness to capitalize on the market opportunity as soon as regulatory and legal conditions permit.
Manufacturing and Quality Compliance
The pre-approval inspection completed in 2025 at the Roorkee solid dosage facility was a critical prerequisite for the tentative approval. Successful completion of this inspection confirms that the manufacturing site meets the USFDA (搜索)'s current Good Manufacturing Practice (cGMP) requirements for producing the Pantoprazole Sodium Delayed Release Oral Suspension formulation.
The 40 mg per packet dosage form represents a differentiated offering in the proton pump inhibitor market, providing an alternative administration option for patients who may have difficulty with solid oral dosage forms.